Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $19.57, along with a high estimate of $51.00 and a low estimate of $10.35. A 38.75% drop is ...

Diabetes technology company Tandem Diabetes Care (NASDAQ:TNDM) in Q1 CY2025, with sales up 22.3% year on year to $234.4 million. The company expects the full year’s revenue to be around $1 billion, ...

Shares of Tandem Diabetes Care (NASDAQ: TNDM) climbed 10.9% on Thursday despite weaker-than-expected quarterly results from the diabetes treatment device company. The market appears to be focused on ...

Truist analyst Richard Newitter raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $14 and keeps a Hold rating on the shares as ...

Tandem Diabetes Care, Inc. TNDM is likely to grow in the coming quarters due to its impressive streak of new product offerings. The company is actively pursuing growth through strategic acquisitions, ...

During the last three months, 4 analysts shared their evaluations of Tandem Diabetes Care TNDM, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of their ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today presented new real-world insights from a survey on Tandem Mobi ...

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced it has signed a multi-year collaboration agreement ...

Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2025 results after the financial markets close on Wednesday, ...

Tandem Diabetes Care's iOS app and insulin pump has made more than 100 people need medical care, resulting in two hospitalizations this year so far. Tandem Diabetes recalled 85,863 devices in May and ...

Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of ...

Tandem Diabetes delivered weaker-than-expected Q4 results but followed with strong forward guidance. The company launched four new products in the U.S. last quarter. For its fourth quarter of 2023, ...